Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of locoregional hyperthermia plus intravesical mitomycin C for non-muscle invasive bladder cancer
NL-OMON24485Active, not recruiting
- Sponsor
- AMC Health
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC), sponsored by AMC Health. Primary endpoints: Feasibility and Toxicity. Started Mar 2009; status: active, not recruiting.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON24485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24485.